• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Excitonic and vibrational coherence in artificial photosynthetic systems studied by negative-time ultrafast laser spectroscopy
  Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminobenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Aminobenzoic acids and derivatives

(4-Aminophenyl)-pyrrolidin-1-yl-methanone and its Role in CAS No. 56302-41-1 in Modern Pharmaceutical Research

(4-Aminophenyl)-pyrrolidin-1-yl-methanone is a multifunctional organic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its unique structural features and potential therapeutic applications. As a derivative of pyrrolidinone, this compound exhibits a combination of aromatic and heterocyclic functionalities, which are critical for its interaction with biological targets. The CAS No. 56302-41-1 designation confirms its chemical identity, while the molecular structure—comprising a 4-aminophenyl group linked to a pyrrolidin-1-yl ring through a methanone moiety—provides a foundation for its diverse pharmacological properties.

Recent studies have highlighted the importance of 4-aminophenyl groups in modulating the biological activity of small molecules. These groups are known to interact with enzymes and receptors through hydrogen bonding and π-π stacking interactions, which are essential for drug-target recognition. The pyrrolidin-1-yl ring, a five-membered heterocyclic system, further enhances the compound’s stability and functional versatility. The methanone functional group, which serves as the bridge between the aromatic and heterocyclic moieties, contributes to the compound’s solubility and reactivity in various chemical environments.

Current research on (4-aminophenyl)-pyrrolidin-1-yl-methanone has focused on its potential as a lead compound for the development of novel therapeutics. A 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits promising anti-inflammatory activity by inhibiting the NF-κB signaling pathway, a key regulator of inflammatory responses. The study also identified the compound’s ability to modulate cytokine production, making it a candidate for the treatment of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the compound’s potential in neuropharmacology. Researchers at the University of Tokyo have reported that (4-aminophenyl)-pyrrolidin-1-yl-methanone shows neuroprotective effects in in vitro models of Parkinson’s disease. The mechanism of action appears to involve the inhibition of mitochondrial dysfunction and the reduction of oxidative stress, which are hallmark features of neurodegenerative disorders. These findings underscore the compound’s potential as a therapeutic agent for neurological conditions.

The synthesis of (4-aminophenyl)-pyrrolidin-1-yl-methanone has been optimized using modern organic chemistry techniques to improve yield and purity. A 2022 paper in Organic & Biomolecular Chemistry described a novel catalytic approach involving palladium-mediated coupling reactions to efficiently construct the molecule. This method not only reduces the number of synthetic steps but also minimizes the use of hazardous reagents, aligning with the principles of green chemistry. The ability to produce high-purity samples is crucial for subsequent biological testing and drug development.

From a pharmacokinetic perspective, the compound’s properties are being evaluated for its potential as an oral medication. Studies have shown that the 4-aminophenyl group enhances the compound’s solubility in aqueous environments, while the pyrrolidin-3-yl ring contributes to its metabolic stability. These characteristics are essential for ensuring that the compound remains active in the bloodstream long enough to exert its therapeutic effects. Additionally, the methanone group may facilitate the formation of prodrug derivatives, which could improve the compound’s bioavailability.

Recent advancements in computational chemistry have further expanded the understanding of (4-aminophenyl)-pyrrolidin-1-yl-methanone’s biological activity. Molecular docking studies have revealed that the compound can bind to multiple protein targets, including enzyme inhibitors and ion channels. This broad-spectrum interaction suggests that the compound may have applications beyond its current therapeutic focus, potentially opening new avenues for drug discovery. Machine learning models are now being employed to predict the compound’s activity against a wider range of targets, accelerating the identification of novel therapeutic applications.

The compound’s role in material science is another emerging area of research. Its unique chemical structure allows it to serve as a building block for the development of functional polymers and nanomaterials. A 2024 study in Advanced Materials demonstrated that (4-aminophenyl)-pyrrolidin-1-yl-methanone can be incorporated into polymer matrices to create materials with enhanced mechanical properties and thermal stability. These materials have potential applications in the production of advanced composites for aerospace and biomedical engineering.

Despite its promising properties, challenges remain in the development of (4-aminophenyl)-pyrrolidin-1-yl-methanone as a therapeutic agent. One of the primary obstacles is ensuring its specificity for target biological pathways while minimizing off-target effects. Ongoing research is focused on modifying the compound’s structure to enhance its selectivity and reduce potential side effects. Additionally, the compound’s long-term safety profile must be thoroughly evaluated through clinical trials to ensure its suitability for human use.

In conclusion, (4-aminophenyl)-pyrrolidin-1-yl-methanone represents a significant advancement in the field of pharmaceutical chemistry. Its unique chemical structure and diverse biological activities make it a valuable candidate for the development of novel therapeutics. Continued research into its synthesis, pharmacological properties, and potential applications will be critical in unlocking its full potential as a drug candidate and material science innovation.

For further information on the latest developments in the study of CAS No. 56302-41-1, researchers are encouraged to consult recent publications in the fields of medicinal chemistry, pharmacology, and materials science. These studies provide insights into the compound’s role in modern science and its potential impact on future medical and industrial applications.

• 8002-03-7(Peanut Oil)
• 3389-54-6(1-benzoylpyrrolidine)
• 34062-68-5(Benzamide, N,N'-1,4-butanediylbis[4-amino-)
• 51207-85-3(4-Amino-N,N-diethylbenzamide)
• 51207-84-2(4-Amino-N-butylbenzamide)
• 42837-37-6(4-(piperidine-1-carbonyl)aniline)
• 79868-19-2(4-amino-N,N-dipropylbenzamide)
• 832103-05-6(Pyrrolidine, 1-[(6-amino-2-naphthalenyl)carbonyl]-)
• 85592-78-5(Benzamide, 4-amino-N-methyl-N-(phenylmethyl)-)
• 80020-05-9(4-(pyrrolidine-1-carbonyl)benzaldehyde)